Trillium Asset Management LLC Sells 770 Shares of Quest Diagnostics (DGX)

Trillium Asset Management LLC trimmed its holdings in shares of Quest Diagnostics (NYSE:DGX) by 0.7% during the first quarter, HoldingsChannel.com reports. The fund owned 113,867 shares of the medical research company’s stock after selling 770 shares during the quarter. Trillium Asset Management LLC’s holdings in Quest Diagnostics were worth $11,421,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Wagner Wealth Management LLC bought a new position in Quest Diagnostics during the fourth quarter worth about $106,000. Fuller & Thaler Asset Management Inc. acquired a new stake in Quest Diagnostics during the fourth quarter worth about $118,000. Cerebellum GP LLC acquired a new stake in Quest Diagnostics during the fourth quarter worth about $128,000. Assetmark Inc. grew its stake in Quest Diagnostics by 139.5% during the fourth quarter. Assetmark Inc. now owns 1,473 shares of the medical research company’s stock worth $145,000 after buying an additional 858 shares in the last quarter. Finally, Icon Wealth Partners LLC acquired a new stake in Quest Diagnostics during the fourth quarter worth about $147,000. 88.28% of the stock is currently owned by institutional investors and hedge funds.

DGX opened at $102.15 on Monday. Quest Diagnostics has a 1-year low of $90.10 and a 1-year high of $112.96. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.14 and a current ratio of 1.23. The company has a market capitalization of $13.87 billion, a PE ratio of 18.92, a P/E/G ratio of 2.02 and a beta of 0.71.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, April 19th. The medical research company reported $1.52 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.52. Quest Diagnostics had a net margin of 10.19% and a return on equity of 15.44%. The company had revenue of $1.88 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same period last year, the company posted $1.33 EPS. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. analysts expect that Quest Diagnostics will post 6.61 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, July 23rd. Stockholders of record on Monday, July 9th will be paid a $0.50 dividend. The ex-dividend date is Friday, July 6th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.96%. Quest Diagnostics’s payout ratio is currently 37.04%.

In related news, VP Robert A. Klug sold 1,157 shares of Quest Diagnostics stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $103.66, for a total transaction of $119,934.62. Following the sale, the vice president now directly owns 5,137 shares in the company, valued at approximately $532,501.42. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Jon R. Cohen sold 83,669 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $104.20, for a total transaction of $8,718,309.80. Following the sale, the senior vice president now owns 115,426 shares in the company, valued at $12,027,389.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 100,013 shares of company stock worth $10,385,983. 1.79% of the stock is currently owned by corporate insiders.

A number of equities research analysts have issued reports on DGX shares. Zacks Investment Research downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 25th. Canaccord Genuity increased their price objective on shares of Quest Diagnostics from $113.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, March 19th. Credit Suisse Group upgraded shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and set a $107.00 price objective on the stock in a research note on Tuesday, February 13th. Goldman Sachs started coverage on shares of Quest Diagnostics in a research note on Monday, January 29th. They set a “buy” rating and a $117.00 price objective on the stock. Finally, Morgan Stanley upgraded shares of Quest Diagnostics from an “underweight” rating to an “equal weight” rating and set a $103.00 price objective on the stock in a research note on Wednesday, March 14th. Fourteen analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $108.33.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply